109 related articles for article (PubMed ID: 25477122)
1. CX-5461 inhibits RNA Pol I in blood cancers.
Cancer Discov; 2014 Dec; 4(12):OF5. PubMed ID: 25477122
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
3. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
4. Central command.
Leslie M
Science; 2014 Aug; 345(6196):506-7. PubMed ID: 25082681
[No Abstract] [Full Text] [Related]
5. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
[TBL] [Abstract][Full Text] [Related]
7. Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
Leung AWY; Anantha M; Dragowska WH; Wehbe M; Bally MB
J Control Release; 2018 Sep; 286():1-9. PubMed ID: 30016731
[TBL] [Abstract][Full Text] [Related]
8. The Selective RNA Polymerase I Inhibitor CX-5461 Mitigates Neointimal Remodeling in a Modified Model of Rat Aortic Transplantation.
Dai C; Sun M; Wang F; Zhu J; Wei Y; Guo X; Ma S; Dong B; Wang G; Jiang F; Wang J
Transplantation; 2018 Oct; 102(10):1674-1683. PubMed ID: 30247451
[TBL] [Abstract][Full Text] [Related]
9. Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis.
Achiron A; Mashiach R; Zilkha-Falb R; Meijler MM; Gurevich M
J Neuroimmunol; 2013 Oct; 263(1-2):91-7. PubMed ID: 23998422
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.
Kang CW; Hannan KM; Blackburn AC; Loh AHP; Hong KC; Yuan GJ; Hein N; Drygin D; Hannan RD; Coupland LA
Invest New Drugs; 2022 Jun; 40(3):529-536. PubMed ID: 35201535
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater MJ; Poortinga G; Sanij E; Hein N; Peck A; Cullinane C; Wall M; Cluse L; Drygin D; Anderes K; Huser N; Proffitt C; Bliesath J; Haddach M; Schwaebe MK; Ryckman DM; Rice WG; Schmitt C; Lowe SW; Johnstone RW; Pearson RB; McArthur GA; Hannan RD
Cancer Cell; 2012 Jul; 22(1):51-65. PubMed ID: 22789538
[TBL] [Abstract][Full Text] [Related]
12. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.
Martins LR; Lúcio P; Melão A; Antunes I; Cardoso BA; Stansfield R; Bertilaccio MT; Ghia P; Drygin D; Silva MG; Barata JT
Leukemia; 2014 Jan; 28(1):179-82. PubMed ID: 23925046
[No Abstract] [Full Text] [Related]
13. Vosaroxin : a novel antineoplastic quinolone.
Abbas JA; Stuart RK
Expert Opin Investig Drugs; 2012 Aug; 21(8):1223-33. PubMed ID: 22724917
[TBL] [Abstract][Full Text] [Related]
14. Arsenicals in hematologic cancers.
Novick SC; Warrell RP
Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
16. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
17. An update on the management of hematologic malignancies in pregnancy.
Lavi N; Horowitz NA; Brenner B
Womens Health (Lond); 2014 May; 10(3):255-66. PubMed ID: 24956292
[TBL] [Abstract][Full Text] [Related]
18. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
[No Abstract] [Full Text] [Related]
19. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
20. Investigational antibody-drug conjugates for hematological malignancies.
Polson AG; Ho WY; Ramakrishnan V
Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]